Bipolar Disorder and Comorbid Use of Illicit Substances

Area of Science:

• Neuroscience
• Psychiatry
• Genetics

Background:

• Substance use disorders (SUD) frequently co-occur with bipolar disorder (BD), worsening patient outcomes.
• The reasons for this increased risk in BD are not fully understood but may involve shared neurobiological, genetic, and epigenetic factors.
• Current diagnostic approaches rely on clinical interviews due to a lack of specialized instruments.

Purpose of the Study:

• To review the current understanding of SUD in BD.
• To evaluate the efficacy of existing treatments for SUD in BD patients.
• To identify gaps in research and clinical practice for managing this comorbidity.

Main Methods:

• Review of existing literature and clinical trials focusing on SUD in BD.
• Analysis of studies examining pharmacological and psychotherapeutic interventions.
• Assessment of study designs, sample sizes, and evidence quality.

Main Results:

• Limited evidence suggests lithium and valproate may help mood symptoms and reduce substance use in cannabis users with BD.
• Citicoline shows potential in reducing cocaine use among BD patients.
• Psychotherapeutic trials show no significant outcome differences between BD patients with or without SUD.
• Many studies suffer from open-label designs and small sample sizes, limiting generalizability.

Conclusions:

• SUD is a significant comorbidity in BD, impacting clinical outcomes.
• Existing treatments show limited, often low-quality evidence for efficacy.
• There is a critical need for more robust basic research and clinical trials to establish evidence-based best practices for managing SUD in BD.